Design, synthesis and biological evaluation of small molecule fluorescent probes targeting EGFR for tumor detection

Depu Song1, Tengli Ding1, Weibin Zhai1

  • 1School of Pharmacy, Henan University, N. Jinming Ave., Kaifeng, Henan, 475004, China. majing@henu.edu.cn.

The Analyst
|November 10, 2023
PubMed

Insights

Researchers developed a novel fluorescent probe, GP1, that specifically targets and detects cancer cells overexpressing the epidermal growth factor receptor (EGFR). This probe also demonstrates significant anti-tumor activity, offering a promising tool for cancer diagnosis and therapy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Medical Imaging

Background:

  • Epidermal growth factor receptor (EGFR) overexpression is linked to cancer development and metastasis.
  • Targeting EGFR is a key strategy in cancer therapy.
  • Developing probes with dual diagnostic and therapeutic functions is crucial for effective cancer treatment.

Purpose of the Study:

  • To design and synthesize novel EGFR-targeting fluorescent probes.
  • To evaluate the probes' spectroscopic properties, cytotoxicity, and specificity for EGFR-overexpressing cells.
  • To assess the probe's efficacy in live-cell imaging, in vivo xenograft imaging, and anti-tumor activity.

Main Methods:

  • Synthesis of EGFR-targeting probes using a coupling strategy with a 1,8-naphthalimide fluorophore and gefitinib.
  • Spectroscopic analysis and cytotoxicity assays on cell lines with varying EGFR expression.
  • Live-cell fluorescence imaging and in vivo xenograft imaging in a mouse model.
  • In vivo anti-tumor activity assessment.

Main Results:

  • Probe GP1 demonstrated excellent environmental sensitivity and specific response to EGFR-overexpressing tumor cells.
  • GP1 exhibited strong EGFR-specific targeting ability in live-cell and in vivo imaging.
  • GP1 showed competitive displacement of gefitinib, indicating specific EGFR binding.
  • GP1 displayed potent anti-tumor effects in a CT-26 tumor-bearing mouse model.

Conclusions:

  • The developed fluorescent probe GP1 is a highly specific EGFR-targeting ligand.
  • GP1 functions as a 'turn-on' probe, valuable for real-time tumor detection.
  • GP1 shows significant potential as a theranostic tool for cancer diagnosis and treatment.